Pandora Wealth’s Theriva Biologics TOVX Stock Holding History

Pandora Wealth’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4	Closed	-$2	–	287
2025 Q2	$2	Hold	4	–	–	﹤0.01%	298
2025 Q1	$4	Buy	+4	New	+$6	﹤0.01%	265

Other funds holding TOVX

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pandora Wealth's TOVX Position: Q3 2025 in Review

Pandora Wealth sold out of Theriva Biologics (TOVX) in Q3 2025, closing a stake of 4 shares — an estimated $2 sold.

Pandora Wealth first reported a position in TOVX in Q1 2025 and held it in 2 quarters. The position peaked at $4 in Q1 2025. 20 funds tracked by Wall St. Rank hold TOVX as of Q3 2025.

Pandora Wealth reported no remaining Theriva Biologics position as of Q3 2025 after selling out during the quarter.
Pandora Wealth sold 4 Theriva Biologics shares in Q3 2025, an estimated $2.
Pandora Wealth first reported a position in Theriva Biologics in Q1 2025 and held it in 2 quarters.
Pandora Wealth's Theriva Biologics position peaked at $4 in Q1 2025.
20 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2025.

Based on Pandora Wealth's 13F filing for Q3 2025, filed 3 Nov 2025.